Multiple Myeloma
Showing NaN - NaN of 228
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)
Not yet recruiting
- Refractory Multiple Myeloma
- +2 more
-
Boston, Massachusetts
- +2 more
Nov 17, 2023
Multiple Myeloma Trial in Boston (THRIVE-M)
Not yet recruiting
- Multiple Myeloma
- THRIVE-M
-
Boston, MassachusettsMassachusetts General Hospital
Oct 2, 2023
Multiple Myeloma Trial in Worldwide (idecabtagene vicleucel, Lenalidomide, Fludarabine)
Not yet recruiting
- Multiple Myeloma
- idecabtagene vicleucel
- +3 more
-
Gilbert, Arizona
- +107 more
Sep 26, 2023
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)
Not yet recruiting
- Relapsed Cancer
- +2 more
- Isatuximab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 19, 2023
Biomarker for Infection Risk in CLL and MM
Not yet recruiting
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Screening
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
May 3, 2023
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Ciltacabtagene Autoleucel
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 2, 2023
Multiple Myeloma, Stem Cell Transplant Complications Trial in Boston (PARE, Waitlist Control Group)
Not yet recruiting
- Multiple Myeloma
- Stem Cell Transplant Complications
- PARE
- Waitlist Control Group
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 30, 2023
Samples and Clinical Data From Patients With Amyloid Diseases
Recruiting
- Multiple Myeloma
- clonality analysis
- +6 more
-
Boston, MassachusettsBoston University Cancer Research Center
Jan 28, 2023
Multiple Myeloma Trial in Spain, United States (BB2121, CC-220, BMS-986405)
Recruiting
- Multiple Myeloma
- BB2121
- +2 more
-
Birmingham, Alabama
- +33 more
Jan 26, 2023
Multiple Myeloma Trial in United States (Lenalidomide, Daratumumab/rHuPH20)
Recruiting
- Multiple Myeloma
-
Anchorage, Alaska
- +698 more
Jan 24, 2023
Hematologic Malignancy, Blood Cancer, Lymphoma Trial in Boston (Palliative Care, Usual Care)
Recruiting
- Hematologic Malignancy
- +4 more
- Palliative Care
- Usual Care
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Jan 24, 2023
Multiple Myeloma Trial in Boston (Health Through Activity)
Not yet recruiting
- Multiple Myeloma
- Health Through Activity
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Selinexor, Dexamethasone)
Completed
- Multiple Myeloma
-
Birmingham, Alabama
- +60 more
Jan 24, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
-
Little Rock, Arkansas
- +145 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab IV, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Daratumumab IV
- +3 more
-
Birmingham, Alabama
- +211 more
Jan 17, 2023
Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
-
Duarte, California
- +21 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Dara SC, Dara IV)
Active, not recruiting
- Multiple Myeloma
- Dara SC
- Dara IV
-
Boston, Massachusetts
- +145 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab, Bortezomib, Lenalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +3 more
-
Whittier, California
- +113 more
Jan 17, 2023